Compare Agilent Technologies Inc (A) vs SOLAI Limited (SLAI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agilent Technologies Inc vs SOLAI Limited — how do they compare? Agilent Technologies Inc trades at $129.02 (market cap $37.04B), while SOLAI Limited trades at $3.22 (market cap $14.40M). The key difference: Agilent Technologies Inc is far larger — about 2572.2× SOLAI Limited's market cap, and Agilent Technologies Inc pays a 0.78% dividend while SOLAI Limited pays none. Which is the better fit depends on your goals.
| A | SLAI | |
|---|---|---|
Market Cap | $37.04B | $14.40M |
Sector | Health | Technology |
52-Week High | $157.20 | $43.75 |
52-Week Low | $110.24 | $2.74 |
Enterprise Value | $38.59B | $14.04M |
Dividend Yield | 0.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
SLAI trades at $3.27, up 5.48% today, but faces significant financial challenges with negative profitability metrics including a -134.63% net income margin and -$33.88M net loss for 2025. The company recently completed a 7:1 reverse stock split and acquired a 51% stake in NEURALAND while receiving NYSE listing standard notices. Technical indicators show a bearish trend with support at $3 and resistance at $4.
Despite recent acquisitions and product launches, SLAI's persistent losses and negative cash flow present substantial investment risks. The single analyst covering the stock maintains a Hold rating, reflecting cautious sentiment amid ongoing financial restructuring and competitive pressures in the AI infrastructure market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About SOLAI Limited
SOLAI focuses on providing innovative AI-driven software solutions. The company leverages artificial intelligence to enhance digital experiences and optimize business processes for various industries.
Read more on SLAI →
